Ritter Pharmaceuticals, Inc. Prices $5,000,000 Public Offering of Common Stock
2016年10月26日 - 9:00PM
Marketwired
Ritter Pharmaceuticals, Inc. Prices $5,000,000 Public Offering
of Common Stock
LOS ANGELES, CA-(Marketwired - Oct 26, 2016) - Ritter
Pharmaceuticals, Inc. (NASDAQ: RTTR) a pharmaceutical company
developing novel therapeutic products that modulate the human gut
microbiome to treat gastrointestinal diseases with its lead
product, RP-G28, being developed for the treatment of lactose
intolerance, today announced the pricing of an underwritten public
offering of 2,127,660 shares of its common stock at a price to the
public of $2.35. The gross proceeds to Ritter Pharmaceuticals, Inc.
from this offering are expected to be approximately $5,000,000,
before deducting underwriting discounts and commissions and other
estimated offering expenses. Ritter Pharmaceuticals, Inc. has
granted the underwriters a 30-day option to purchase up to an
additional 319,149 shares of common stock to cover over-allotments,
if any. The offering is expected to close on October 31, 2016,
subject to customary closing conditions.
Aegis Capital Corp. acted as the sole book-running manager for
the offering.
The offering described above is being made pursuant to a shelf
registration statement on Form S-3 (File No. 333-213087), which was
declared effective by the United States Securities and Exchange
Commission ("SEC") on August 23, 2016. A preliminary prospectus
supplement and accompanying base prospectus relating to the
offering was filed with the SEC and a final prospectus supplement
and accompanying base prospectus will be filed with the SEC.
Electronic copies of the preliminary prospectus supplement and
accompanying base prospectus and, when available, electronic copies
of the final prospectus supplement and accompanying base prospectus
relating to this offering may be obtained by contacting Aegis
Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th
Floor, New York, NY 10019, telephone: 212-813-1010, e-mail:
prospectus@aegiscap.com. Investors may also obtain these documents
at no cost by visiting the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About COMPANY Ritter Pharmaceuticals, Inc. develops novel
therapeutic products that modulate the human gut microbiome to
treat gastrointestinal diseases. The Company is advancing human gut
health research by exploring the metabolic capacity of gut
microbiota, and translating the functionality of these microbiome
modulators into safe and effective applications. Their lead drug
candidate, RP-G28, has the potential to become the first
FDA-approved drug for lactose intolerance, a condition that affects
more than one billion people worldwide.
Forward-Looking Statements This release may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
related to our release of topline results from our Phase 2b/3
clinical trial of RP-G28. Management believes that these
forward-looking statements are reasonable as and when made.
However, such statements involve a number of known and unknown
risks and uncertainties that could cause the Company's future
results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by
such forward-looking statements. These risks and uncertainties
include, but are not limited to, risks associated with the drug
development process generally, including the outcomes of planned
clinical trials and the regulatory review process. For a discussion
of certain risks and uncertainties affecting Ritter
Pharmaceuticals' forward-looking statements, please review the
Company's reports filed with the Securities and Exchange
Commission, including, but not limited to, its Annual Report on
Form 10-K for the period ended December 31, 2015 and Quarterly
Reports on Form 10-Q for the periods ended March 31, 2016 and June
30, 2016. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
on which they are made. These statements are based on management's
current expectations and Ritter Pharmaceuticals does not undertake
any responsibility to revise or update any forward-looking
statements contained herein, except as expressly required by
law.
Corporate Communications Contact: For Media: Chris Hippolyte
chippolyte@theruthgroup.com (646) 536-7023 For Investors: David
Burke dburke@theruthgroup.com (646) 536-7009
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024